I'm not trying to interrupt the narrative here, but are clinical study results for NNZ-2591 that impressive? The market is probably suggesting that the drug isn't that effective and is at risk of regulatory denial. Therefore the SP reflects anxiety about plateauing sales of Daybue and delayed rollout to ROW.
Share Price, page-11153
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.94 |
Change
-0.290(1.79%) |
Mkt cap ! $2.037B | |||
| Open | High | Low | Value | Volume |
| $16.33 | $16.37 | $15.78 | $10.73M | 671.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1500 | $15.90 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.02 | 1422 | 2 |
View Market Depth
| Last trade - 16.10pm 13/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |